HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE COVER ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Submit a letter to the editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Haas, G. P. Articles by Sakr, W. A. Search for Related Content PubMed PubMed Citation Articles by Haas, G. P. Articles by Sakr, W. A.

CA: A Cancer Journal for Clinicians, Vol 47, Issue 5 273-287, Copyright © 1997 by American Cancer Society

ARTICLES

Epidemiology of prostate cancer

G. P. Haas and W. A. Sakr
Department of Urology, State University of New York Health Sciences Center, Syracuse, USA.

Malignant transformation of the prostate and progression of carcinoma appear to be the consequence of a complex series of initiation and promotional events under genetic and environmental influences. Increased incidence of the condition may be the result of improved detection, greater awareness of the condition, and possibly an increased life expectancy accompanied by a decrease in competing causes of death rather than a true increase in the prevalence of the disease. The marked racial and geographic differences are probably multifactorial, with genetic, environmental, and possibly social influences affecting progression of the disease. Among several risk factors, evidence for the familial inheritance of some prostate cancers is compelling. Dietary influences, hormonal milieu, and the role of environmental carcinogens are currently under intense investigation. As further risk factors are identified, it will become increasingly important to identify individuals at increased risk for the disease. These men should undergo regular evaluation with state-of-the-art methods.

This article has been cited by other articles:

				A. D. Darnel, E. Behmoaram, R. T. Vollmer, J. Corcos, K. Bijian, K. Sircar, J. Su, J. Jiao, M. A. Alaoui-Jamali, and T. A. Bismar Fascin Regulates Prostate Cancer Cell Invasion and Is Associated with Metastasis and Biochemical Failure in Prostate Cancer Clin. Cancer Res., February 15, 2009; 15(4): 1376 - 1383. [Abstract] [Full Text] [PDF]

				T. IGUCHI, S. SUGITA, C. Y. WANG, N. B. NEWMAN, T. NAKATANI, and G. P. HAAS MnSOD Genotype and Prostate Cancer Risk as a Function of NAT Genotype and Smoking Status In Vivo, January 1, 2009; 23(1): 7 - 12. [Abstract] [Full Text] [PDF]

				J. S. Kasper and E. Giovannucci A Meta-analysis of Diabetes Mellitus and the Risk of Prostate Cancer. Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2056 - 2062. [Abstract] [Full Text] [PDF]

				F. Kamangar, G. M. Dores, and W. F. Anderson Patterns of Cancer Incidence, Mortality, and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the World J. Clin. Oncol., May 10, 2006; 24(14): 2137 - 2150. [Abstract] [Full Text] [PDF]

				C. K. Gwede and R. J. McDermott Prostate Cancer Screening Decision Making Under Controversy: Implications for Health Promotion Practice Health Promot Pract, January 1, 2006; 7(1): 134 - 146. [Abstract] [PDF]

				S. K. Srivastava, D. Xiao, K. L. Lew, P. Hershberger, D. M. Kokkinakis, C. S. Johnson, D. L. Trump, and S. V. Singh Allyl isothiocyanate, a constituent of cruciferous vegetables, inhibits growth of PC-3 human prostate cancer xenografts in vivo Carcinogenesis, October 1, 2003; 24(10): 1665 - 1670. [Abstract] [Full Text] [PDF]

				K. A. Nelson and J. S. Witte Androgen Receptor CAG Repeats and Prostate Cancer Am. J. Epidemiol., May 15, 2002; 155(10): 883 - 890. [Abstract] [Full Text] [PDF]

				R. E. Myers, T. Hyslop, K. Jennings-Dozier, T. A. Wolf, D. Y. Burgh, J. A. Diehl, C. Lerman, and G. W. Chodak Intention to Be Tested for Prostate Cancer Risk among African-American Men Cancer Epidemiol. Biomarkers Prev., December 1, 2000; 9(12): 1323 - 1328. [Abstract] [Full Text]

				A. M. Bayoumi, A. D. Brown, and A. M. Garber Cost-Effectiveness of Androgen Suppression Therapies in Advanced Prostate Cancer J Natl Cancer Inst, November 1, 2000; 92(21): 1731 - 1739. [Abstract] [Full Text] [PDF]

				G. M. Solomon and T. Schettler Environment and health: 6. Endocrine disruption and potential human health implications Can. Med. Assoc. J., November 1, 2000; 163(11): 1471 - 1476. [Full Text] [PDF]

				E. Hawk, R. A. Breslow, and B. I. Graubard Male Pattern Baldness and Clinical Prostate Cancer in the Epidemiologic Follow-Up of the First National Health and Nutrition Examination Survey Cancer Epidemiol. Biomarkers Prev., May 1, 2000; 9(5): 523 - 527. [Abstract] [Full Text]

				K. A. Moffatt, W. U. Johannes, and G. J. Miller 1{{alpha}},25-Dihydroxyvitamin D3 and Platinum Drugs Act Synergistically to Inhibit the Growth of Prostate Cancer Cell Lines Clin. Cancer Res., March 1, 1999; 5(3): 695 - 703. [Abstract] [Full Text] [PDF]

				C. A. Lawton, D. Grignon, J. H. Newhouse, P. F. Schellhammer, and D. A. Kuban Oncodiagnosis Panel: 1997 : Prostatic Carcinoma RadioGraphics, January 1, 1999; 19(1): 185 - 203. [Full Text] [PDF]

				A. M. Evens, T. M. Lestingi, and J. D. Bitran Intermittent Androgen Suppression as a Treatment for Prostate Cancer: A Review Oncologist, December 1, 1998; 3(6): 419 - 423. [Abstract] [Full Text]